These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
911 related articles for article (PubMed ID: 19850784)
1. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Leu L; Mohassel L Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784 [TBL] [Abstract][Full Text] [Related]
2. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Iland HJ; Wei A; Seymour JF Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016 [TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide, a therapeutic agent for APL. Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843 [TBL] [Abstract][Full Text] [Related]
4. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
5. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Calleja EM; Warrell RP Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887 [TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572 [TBL] [Abstract][Full Text] [Related]
7. The design of selective and non-selective combination therapy for acute promyelocytic leukemia. Jing Y; Waxman S Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide in the treatment of haematological malignancies. Kwong YL Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417 [TBL] [Abstract][Full Text] [Related]
9. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Lengfelder E; Hofmann WK; Nowak D Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379 [TBL] [Abstract][Full Text] [Related]
10. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
12. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315 [TBL] [Abstract][Full Text] [Related]
13. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Lachaine J; Mathurin K; Barakat S; Couban S Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894 [TBL] [Abstract][Full Text] [Related]
15. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361 [TBL] [Abstract][Full Text] [Related]
16. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204 [TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309 [TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. Douer D; Tallman MS J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332 [TBL] [Abstract][Full Text] [Related]
20. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. Zhang L; Zhu X; Zou Y; Chen Y; Chen X Int J Hematol; 2011 Feb; 93(2):199-205. PubMed ID: 21287409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]